Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury.

OBJECTIVES The aim of this study was to evaluate the correlation of neuron specific enolase (NSE), protein S100B and time-profile of Glasgow Coma Score (GCS) development with metallothionein (MT) blood levels in patients with traumatic brain injury (TBI) during 10 days of hospitalization. Patients were divided into 2 groups with respect to NSE and S100B levels - with (group I) and without (group II) GCS improvement. METHODS Serum NSE and S100B concentrations were measured by immunochemical methods; serum metallothionein concentration by electrochemical technique. Cortical biopsies were investigated immunohistochemically and by electron microscope. A cDNA microarray containing 700 gene probes was used to study the changes in gene expression in the ipsilateral cortex. RESULTS Values of MT in the blood of group I showed a non-significant decrease compared to group II during 1-3 days after admission. There was an increase of MT during 4-8 days in comparison with values of 1-3 days. The highest value of MT during hospitalization was found in a patient with diffuse axonal injury (group II). The data of cDNA microarray suggested an increase in expression of gene transcripts for oxygen free radical scavenger proteins corresponding with the increase of MT during 4-8 days in both groups. CONCLUSIONS The experimental data indicate that monitoring the content of MT in patients with trauma brain injury would be a suitable approach to evaluate the degree of injury or duration of prolonging unconsciousness, particularly in diagnosis of diffuse axonal injury.

[1]  René Kizek,et al.  Attomole voltammetric determination of metallothionein , 2006 .

[2]  J. Kukacka,et al.  [Biochemical and immunohistochemical markers of brain injury]. , 2006, Soudni lekarstvi.

[3]  M. Penkowa Metallothioneins are multipurpose neuroprotectants during brain pathology , 2006, The FEBS journal.

[4]  A. Quintana,et al.  Specificity and divergence in the neurobiologic effects of different metallothioneins after brain injury , 2006, Journal of neuroscience research.

[5]  V. Adam,et al.  Changes of content of glutathione and metallothionein at plant cells and invertebrates treated by platinum group metals , 2006 .

[6]  S. Nolan Traumatic Brain Injury: A Review , 2005, Critical care nursing quarterly.

[7]  T. Beems,et al.  Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury , 2004, Neurology.

[8]  James C Vickers,et al.  Cytoskeletal and Morphological Alterations Underlying Axonal Sprouting after Localized Transection of Cortical Neuron AxonsIn Vitro , 2003, The Journal of Neuroscience.

[9]  A. Brawanski,et al.  Does bungee jumping release S-100B protein? , 2002, Journal of Clinical Neuroscience.

[10]  A. Brawanski,et al.  Early S-100B serum level correlates to quality of life in patients after severe head injury , 2002, Brain injury.

[11]  A. Ebert,et al.  Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. , 2000, Journal of neurotrauma.

[12]  A. Brawanski,et al.  Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. , 1999, The Journal of trauma.

[13]  J. Hidalgo,et al.  CNS Wound Healing Is Severely Depressed in Metallothionein I- and II-Deficient Mice , 1999, The Journal of Neuroscience.

[14]  T. Moos,et al.  Disruption of the blood‐brain interface in neonatal rat neocortex induces a transient expression of metallothionein in reactive astrocytes , 1995, Glia.

[15]  S. Ojeda,et al.  A rapid microprocedure for isolating RNA from multiple samples of human and rat brain , 1985, Journal of Neuroscience Methods.

[16]  A. Brawanski,et al.  Comparison of serial S-100 and NSE serum measurements after severe head injury , 2005, Acta Neurochirurgica.

[17]  V. Adam,et al.  Fast and sensitive electrochemical detection of native,denatured, and aggregated forms of tumor supressor protein p53 , 2004 .